SCHEMBL27411002

SCHEMBL27411002

CC(C)(C)c1c(-c2csc(N3[C@@H]4CCC[C@H]3CC4)n2)ccc(F)c1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 7/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ TYR P14679 1/20 0.31
▸ PLAU P00749 1/20 0.31
▸ CYP1A2 P05177 1/20 0.30
▸ CYP3A4 P08684 1/20 0.30
▸ CYP2C9 P11712 1/20 0.30
▸ CYP2C19 P33261 1/20 0.30
▸ L3MBTL1 Q9Y468 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ LMNA P02545 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ TSHR P16473 1/20 0.30
▸ MAPK1 P28482 1/20 0.30
▸ HTT P42858 1/20 0.30
▸ MCOLN3 Q8TDD5 1/20 0.30
▸ MAOA P21397 1/20 0.30
▸ MAOB P27338 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27411038 0.99 AR (0.41) ARSMN1; SMN2NPC1RAB9ATYR
SCHEMBL27413224 0.89 AR (0.43) ARSMN1; SMN2NPC1RAB9A
SCHEMBL27411006 0.89 AR (0.35) ARSMN1; SMN2NPC1RAB9ATYR
SCHEMBL27411004 0.89 AR (0.33) ARSMN1; SMN2NPC1RAB9ATYR
SCHEMBL27411008 0.83 AR (0.36) ARSMN1; SMN2TYR
SCHEMBL25942472 0.81 AR (0.54) ARSMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL27413226 0.78 AR (0.36) ARSMN1; SMN2NPC1RAB9AMAPK1
SCHEMBL27413227 0.78 AR (0.38) ARSMN1; SMN2NPC1RAB9AMAPK1
SCHEMBL27413395 0.78 AR (0.46) ARSMN1; SMN2NPC1RAB9ACYP1A2
SCHEMBL27413287 0.78 AR (0.46) ARSMN1; SMN2NPC1RAB9ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240207415-A1 BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR DBD THERAPEUTICS, LLC 2024-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240207415-A1 BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR AR, ADRM1, PSMA3 AR 1/4885SMN1; SMN2 4546/4885NPC1 3776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback